E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
23 mars 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a paper...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore's Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study
21 mars 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of a...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank
14 mars 2023 08h30 HE | electroCore, Inc.
ROCKAWAY, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it does not have direct exposure...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting
13 mars 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that data from a sham controlled...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at 35th Annual Roth Conference
09 mars 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, NJ, March 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Fourth Quarter and Full Year 2022 Financial Results
08 mars 2023 16h05 HE | electroCore, Inc.
Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J.,...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Regains Compliance with Nasdaq Listing Requirements
07 mars 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received notice from...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce Fourth Quarter and Year Ended December 31, 2022 Financial Results on Wednesday, March 8
01 mars 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa
21 févr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
16 févr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and...